Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-α on renal cell carcinoma cell lines by protein biochip technology

International Journal of Oncology

Volumn 28, Issue 4, 2006, Pages 965-970

  Nakamura, Kogenta ^a   Yoshikawa, Kazuhiro ^a   Yamada, Yoshiaki ^a   Saga, Shinsuke ^a   Aoki, Shigeyuki ^a   Taki, Tomohiro ^a   Tobiume, Motoi ^a   Shimazui, Toru ^b   Akaza, Hideyuki ^b   Honda, Nobuaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Anti proliferative; Interferon ; Renal cell carcinoma cell lines; SELDI

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CELL EXTRACT; PROTEIN;

ARTICLE; CHEMISTRY; DRUG RESISTANCE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PATHOLOGY; PROTEIN DATABASE; PROTEIN MICROARRAY; PROTEOMICS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL EXTRACTS; CELL LINE, TUMOR; DATABASES, PROTEIN; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEINS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 33744736609     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.4.965     Document Type: Article

References (20)

1. De Kernion JB and Berry D: The diagnosis and treatment of renal cell carcinoma. Cancer 45: 1947-1956, 1980.
2. Patel NP and Lavengood RW: Renal cell cancer: natural history and results of treatment. J Urol 119: 722-726, 1997.
3. Wirth MP: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283-283, 1993.
4. Jenkins RE and Pennington SR: Arrays for protein expression profiling: towards a viable alternative to two-dimensional gel electrophoresis? Proteomics 1: 13-13, 2001.
5. Merchant M and Weinberger SR: Recent advances in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21: 1164-1164, 2000.
6. Weinberger SR, Dalmasso EA and Fung ET: Current achievements using ProteinChip Array technology. Curr Opin Chem Biol 6: 86, 2002.
7. Fung ET, Wright GL Jr and Dalmasso EA: Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2: 643-643, 2000.
8. Adam B-L, Vlahou A, Semmes OJ and Wright GL Jr: Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 1: 1264-1270, 2001.
9. Paweletz CP, Gillespie JW, Ornstein DK, Simone NL, Brown MR and Cole K: Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res 49: 34-42, 2000.
10. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA and Steinberg SM: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577, 2002.
11. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW and Schellhammer PF: Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 61: 6029-6033, 2001.
12. Wright GL Jr, Cazares LH, Leung S-M, Nasim S, Adam B-L and Yip T-T: ProteinChip® surface enhanced laser desorption/ionization(SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 2: 264-276, 1999.
13. Nanus DM, Preffer LM, Bander NH, Bahri S and Albino AP: Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res 50: 4190-4194, 1990.
14. Geng Y, Biffi A, Engelstein D, Ronch E, Faustini M and Lai HK: Expression of the kidney-associated differentiation glycoprotein gp160 and resistance to the antitumor effects of interferon alpha in renal cell carcinoma. Anticancer Res 18A: 1-7, 1998.
15. Darnell JE Jr, Kerr IM and Stark GM: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994.
16. Ihle J: STATs: signal transducers and activators of transcription. Cell 84: 331-334, 1996.
17. Schindler C and Darnell JE Jr: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64: 621-651, 1995.
18. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S and Uddin S: Interferon-α resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91: 570-576, 1998.
19. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S and Belinger C: Defective JAK-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-α. Int J Cancer 85: 720-725, 2000.
20. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P and Tam ND: Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3γ. J Biol Chem 272: 28779-28785, 1997.